ReviewMedComm2026
Varicella Zoster Virus Infection: Clinical Features, Molecular Pathogenesis, Treatment, and Prevention.
Review in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk prediction models for postherpetic neuralgia: a systematic review and meta-analysis.Frontiers in neurologyPooled it
- Article
- Novel Indolinyl Compounds as Helicase Primase Inhibitors for Treating Viral Infections, in particular, Herpesvirus Infections.ACS medicinal chemistry letters · 2026Article
- Neonatal varicella complicated by Staphylococcus aureus lung abscess in a preterm infant: a case report.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Varicella zoster virus (VZV) is a ubiquitous human herpesvirus that establishes lifelong latency and causes herpes zoster (HZ) upon reactivation, posing a growing clinical challenge in aging populations. The incidence of HZ increases sharply with age and immunocompromised states, and its clinical burden extends well beyond cutaneous disease to include postherpetic neuralgia, neurological complications, and systemic involvement. At the mechanistic level, HZ reflects a dynamic interplay between viral reactivation, host immune surveillance, and virus-induced neuronal injury. Despite substantial progress in antiviral therapy and vaccination, many interventions remain focused on individual stages of the disease process, and the translation of molecular insights into comprehensive clinical strategies remains incomplete. In this review, we synthesize current knowledge of VZV epidemiology, structure, and life cycle, and provide an integrated overview of clinical manifestations and molecular pathogenesis, with particular emphasis on latency, reactivation, and immune evasion. We further summarize advances in diagnostic technologies and discuss therapeutic strategies targeting viral replication, inflammatory complications, and long-term sequelae, alongside preventive approaches. By linking disease mechanisms with clinical management, this review highlights key challenges and emerging directions for improving the prevention and treatment of HZ and provides a framework for translating fundamental discoveries into more effective interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.